Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 482.38 thousand shares for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2024-11-18
- Neurogene Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-09-30 was 0.00 shares.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-06-30 was 0.00 shares.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-03-31 was 482.38K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month |
|---|---|---|---|
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-18 | 482.38K shares 10-Q · filed 2024-11-18 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 482.38K shares 10-Q · filed 2024-08-09 | |
| 2024-03-31 | 482.38K shares 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |